PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Avanafil - Erectile dysfunction
PAD Profile : Avanafil - Erectile dysfunction
Keywords :
ED, impotence, phosphodiesterase type 5 inhibitors, PDE5 inhibitors, PDE-5
Brand Names Include :
Spedra
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands APC have reviewed the treatments for erectile dysfunction.
Avanafil remains non-formulary.
Sildenafil or tadalafil are the preferred treatment options.
Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use.
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction